MARCUZZI, ANNALISA
 Distribuzione geografica
Continente #
NA - Nord America 9.024
EU - Europa 5.020
AS - Asia 3.077
SA - Sud America 421
Continente sconosciuto - Info sul continente non disponibili 324
AF - Africa 117
OC - Oceania 9
Totale 17.992
Nazione #
US - Stati Uniti d'America 8.913
PL - Polonia 2.519
SG - Singapore 1.109
CN - Cina 738
SE - Svezia 494
IT - Italia 455
VN - Vietnam 350
BR - Brasile 321
HK - Hong Kong 321
UA - Ucraina 318
DE - Germania 232
FR - Francia 216
FI - Finlandia 143
GB - Regno Unito 141
RU - Federazione Russa 117
KR - Corea 108
TR - Turchia 107
BD - Bangladesh 103
NL - Olanda 97
BG - Bulgaria 78
IE - Irlanda 73
IN - India 64
CA - Canada 51
BE - Belgio 30
MA - Marocco 30
MX - Messico 29
JP - Giappone 28
IQ - Iraq 27
SN - Senegal 27
AR - Argentina 24
VE - Venezuela 23
ZA - Sudafrica 19
ES - Italia 17
CH - Svizzera 16
AT - Austria 14
CL - Cile 13
CO - Colombia 13
GR - Grecia 13
SA - Arabia Saudita 12
IL - Israele 11
TN - Tunisia 11
EC - Ecuador 9
EU - Europa 9
PK - Pakistan 9
RO - Romania 9
AE - Emirati Arabi Uniti 8
CR - Costa Rica 8
PH - Filippine 8
AU - Australia 7
MY - Malesia 7
TH - Thailandia 7
AZ - Azerbaigian 6
DK - Danimarca 6
ID - Indonesia 6
JO - Giordania 6
LT - Lituania 6
PY - Paraguay 6
UZ - Uzbekistan 6
DZ - Algeria 5
NP - Nepal 5
PE - Perù 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AL - Albania 4
GA - Gabon 4
JM - Giamaica 4
KE - Kenya 4
NG - Nigeria 4
PT - Portogallo 4
AM - Armenia 3
AO - Angola 3
DO - Repubblica Dominicana 3
EG - Egitto 3
GE - Georgia 3
HN - Honduras 3
IR - Iran 3
KZ - Kazakistan 3
LU - Lussemburgo 3
UY - Uruguay 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BO - Bolivia 2
BS - Bahamas 2
GT - Guatemala 2
HR - Croazia 2
HU - Ungheria 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
CD - Congo 1
CU - Cuba 1
CY - Cipro 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
FJ - Figi 1
FK - Isole Falkland (Malvinas) 1
Totale 17.658
Città #
Warsaw 2.449
Ashburn 953
Fairfield 899
Woodbridge 840
Singapore 738
Houston 674
Ann Arbor 625
Chandler 506
Seattle 434
Wilmington 417
San Jose 342
Hong Kong 311
Jacksonville 298
Cambridge 294
Beijing 166
Chicago 153
Princeton 136
Los Angeles 123
Boardman 120
Trieste 111
Ho Chi Minh City 110
Seoul 103
Dallas 95
Dearborn 84
Columbus 78
Council Bluffs 77
Sofia 77
Lauterbourg 75
Hanoi 74
Dublin 72
Izmir 72
Hefei 71
Santa Clara 67
Zgierz 59
New York 52
Frankfurt am Main 51
Munich 50
Milan 47
Moscow 47
Buffalo 45
The Dalles 39
Amsterdam 38
London 38
Salt Lake City 38
São Paulo 38
Helsinki 37
San Diego 37
Dong Ket 36
Falls Church 35
Orem 34
Düsseldorf 30
Phoenix 29
Brussels 27
Dakar 27
Grafing 26
Casablanca 25
Elk Grove Village 24
Shanghai 24
Jinan 23
Des Moines 22
Tokyo 22
Tampa 21
Kunming 20
Chennai 19
Washington 19
Redondo Beach 18
Nanjing 17
Brooklyn 16
Hebei 15
Portsmouth 15
Redwood City 15
Toronto 15
Turku 15
Rome 14
Atlanta 13
Da Nang 13
Guangzhou 13
Haiphong 13
Miano 13
Ankara 12
Johannesburg 12
Montreal 12
Stockholm 11
Brasília 10
Bremen 10
Corinth 10
Denver 10
Miami 10
Nanchang 10
Nuremberg 10
Tianjin 10
Can Tho 9
Fuzhou 9
Mexico City 9
Mumbai 9
Rio de Janeiro 9
San Francisco 9
Santiago 9
Belo Horizonte 8
Hangzhou 8
Totale 13.134
Nome #
The complex interplay between lipids, immune system and interleukins in cardio-metabolic diseases 632
Ex vivo response to mucosal bacteria and muramyl dipeptide in inflammatory bowel disease 502
Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology 456
Alendronate, a double-edged sword acting in the mevalonate pathway 443
Neuronal Dysfunction Associated with Cholesterol Deregulation. 439
Curcumin anti-apoptotic action in a model of intestinal epithelial inflammatory damage 417
To extinguish the fire from outside the cell or to shutdown the gas valve inside? Novel trends in anti-inflammatory therapies 416
Type i interferon-mediated autoinflammation due to DNase II deficiency 411
Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway. 397
Repositioning Of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice 389
Two‑gene mutation in a single patient: Biochemical and functional analysis for a correct interpretation of exome results. 387
Inflammatory bowel disease and patterns of volatile organic compounds in the exhaled breath of children: A case-control study using Ion Molecule Reaction-Mass Spectrometry 385
Pediatric patients with inflammatory bowel disease exhibit increased serum levels of proinflammatory cytokines and chemokines, but decreased circulating levels of macrophage inhibitory protein-1β, interleukin-2 and interleukin-17 362
Monocyte-predominant engraftment, cytokine levels and early transplant-related complications in pediatric hematopoietic stem cell recipients 325
Clinical Genetic Testing of Periodic Fever Syndromes 314
A common genetic background could explain early-onset Crohn's disease. 292
Curcumin and inflammatory bowel disease: Potential andlimits of innovative treatments 289
Antibodies reacting to mimotopes of Simian virus 40 large T antigen, the viral oncoprotein, in sera from children. 288
Altered germinal center reaction and abnormal B cell peripheral maturation in PI3KR1-mutated patients presenting with HIGM-like phenotype 286
The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency. 277
Is autophagy an elective strategy to protect neurons from dysregulated cholesterol metabolism? 277
A comparative analysis of serologic parameters and oxidative stress in osteoarthritis and rheumatoid arthritis: reply to Mishra and colleagues 275
Comments on ''Geranylgeraniol--a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw" by Ziebart T et al. (2011). 274
Decreased cholesterol levels reflect a consumption of anti-inflammatory isoprenoids associated with an impaired control of inflammation in a mouse model of mevalonate kinase deficiency. 272
Cytokine profiles of women with vulvodynia: Identification of a panel of pro-inflammatory molecular targets 269
Defect in mevalonate pathway induces pyroptosis in Raw 264.7 murine monocytes. 264
Cytokine levels in the serum of healthy subjects. 257
Long non-coding RNA gas5 and intestinal mmp2 and mmp9 expression: A translational study in pediatric patients with IBD 256
Natural isoprenoids inhibit LPS-induced-production of cytokines and nitric oxide in aminobisphosphonate-treated monocytes. 255
Mevalonate kinase deficiency and IBD: shared genetic background 250
Comments to the editor concerning the paper entitled "Preclinical renal cancer chemopreventive efficacy of geraniol by modulation of multiple molecular pathways" Shiekh Tanveer Ahmad et al. 248
Microglia activation and interaction with neuronal cells in a biochemical model of mevalonate kinase deficiency 246
Letter to the editor: acute effects of intravenous administration of pamidronate in patients with osteoporosis. 241
Block of the Mevalonate Pathway Triggers Oxidative and Inflammatory Molecular Mechanisms Modulated by Exogenous Isoprenoid Compounds 240
Evolutionary hypothesis of the Mevalonate Kinase Deficiency. 239
Database tools in genetic diseases research. 237
Inflammation profile of four early onset Crohn patients. 234
Targeting farnesyl-transferase as a novel therapeutic strategy for mevalonate kinase deficiency: In vitro and in vivo approaches. 229
Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency. 223
Lovastatin dose-dependently potentiates the pro-inflammatory activity of lipopolysaccharide both in vitro and in vivo 222
Family history in early-onset inflammatory bowel disease 219
Putative modifier genes in mevalonate kinase deficiency 217
Letter: inflammatory bowel disease, complementary and alternative medicine, and genetics 209
The Challenge of Next Generation Sequencing in a Boy with Severe Mononucleosis and EBV-related Lymphoma 206
Farnesyl and geranylgeranyl transferase inhibitors: an anti-inflammatory effect. Comment to "Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells" Haematologica. 2013;98(1):31-40 198
Microcapsule a doppio strato di polisaccaridiutilizzabili come veicoli per la somministrazione oraledi sostanze biologicamente attive 194
Lovastatin induces apoptosis through the mitochondrial pathway in an undifferentiated SH-SY5Y neuroblastoma cell line 192
Serum amyloid A and cholesterol: a pivotal role on inflammation. 190
Mevalonate kinase deficiency: therapeutic targets, treatments, and outcomes 183
Mevalonate Kinase Deficiency and Neuroinflammation: Balance between Apoptosis and Pyroptosis 175
Autoinflammatory syndromes and coeliac disease: One observation and two hypotheses 170
Specific protein profile in cerebrospinal fluid from HIV-1-positive cART-treated patients affected by neurological disorders. 169
Temperature and Drug Treatments in Mevalonate Kinase Deficiency: An Ex Vivo Study 168
New Mechanisms in Autoinflammatory Diseases 168
Geraniol rescues inflammation in cellular and animal models of mevalonate kinase deficiency 166
Lovastatin-induced apoptosis is modulated by geranylgeraniol in a neuroblastoma cell line. 163
MIF plasma level as a possible tool to predict steroid responsiveness in children with idiopathic nephrotic syndrome 156
Mevalonate kinase deficiency: disclosing the role of mevalonate pathway modulation in inflammation. 152
Presence of IL-9 in paired samples of human colostrum and transitional milk. 145
Clarification of the pleiotropic effects of statins on mevalonate pathway and the feedback regulation of isoprenoids requires more comprehensive investigation. 145
Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients 137
Post-Irradiation Hyperamylasemia Is a Prognostic Marker for Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Pediatric Population: A Retrospective Single-Centre Cohort Analysis 135
TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyldipeptide or lipopolysaccharide. 133
Standard treatment–refractory cytomegalovirus encephalitis unmasked by immune reconstitution inflammatory syndrome and successfully treated with virus-specific hyperimmune globulin 133
null 130
Mouse model of mevalonate kinase deficiency: comparison of cytokines and chemokines profile with human patients 128
The effect of clodronate on a mevalonate kinase deficiency cellular model. 126
New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib 118
Role of vitamin D in the pathogenesis of atheromatosis 111
null 109
null 108
Mevalonate kinase deficiency and squalene synthase inhibitor (TAK-475): The balance to extinguish the inflammation 92
null 86
Systemic and neuronal inflammatory markers in a mouse model of mevalonate kinase deficiency: a strain-comparative study. 83
Lysozyme-containing chitosan-coated arginate microspheres for oral immunisation 63
Totale 17.992
Categoria #
all - tutte 45.367
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.367


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022926 0 50 56 59 78 102 58 18 98 91 77 239
2022/20231.384 164 201 118 206 117 246 1 109 145 10 56 11
2023/2024805 33 57 56 54 81 99 160 148 14 9 56 38
2024/20251.692 26 80 159 173 170 106 154 57 208 219 178 162
2025/20264.425 729 154 298 371 384 345 662 145 511 507 184 135
2026/2027186 111 75 0 0 0 0 0 0 0 0 0 0
Totale 17.992